in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in the United States and Brazil.
Hosted on MSN1mon
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...
The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA ...
MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...
(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in ...
“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin ...
“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback